Correlation of response to treatment and HIV genotypic changes during Phase III trials with saquinavir and reverse transcriptase inhibitor combination therapy

AIDS

Volumn 12, Issue 12, 1998, Pages 1465-1474

  Race, Esther ^a   Gilbert, Susan M ^a   Sheldon, Jonathan G ^a   Rose, Jane S L ^a   Moffatt, Alec R ^a   Sitbon, Gisela ^b   Dissanayeke, Shobana R ^a   Cammack, Nick ^a   Duncan, Ian B ^a  

^a ROCHE PRODUCTS LTD   (United Kingdom)

^b Professional Genetics Laboratory   (Sweden)

Author keywords

Combination; Drug sensitivity; Genotypic change; HIV protease; Phenotypic change; Therapy

Indexed keywords

METHIONINE; PROTEINASE INHIBITOR; RNA DIRECTED DNA POLYMERASE INHIBITOR; SAQUINAVIR; VALINE; VIRUS DNA; ZALCITABINE; ZIDOVUDINE;

AMINO ACID SUBSTITUTION; ARTICLE; CLINICAL TRIAL; CONTROLLED STUDY; GENOTYPE; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MONONUCLEAR CELL; NONHUMAN; PHASE 3 CLINICAL TRIAL; PHENOTYPE; PRIORITY JOURNAL; PROVIRUS; VIRUS ISOLATION;

AMINO ACID SEQUENCE; DNA, VIRAL; DRUG RESISTANCE, MICROBIAL; DRUG THERAPY, COMBINATION; GENOTYPE; HIV; HIV INFECTIONS; HIV PROTEASE; HIV PROTEASE INHIBITORS; HUMANS; MICROBIAL SENSITIVITY TESTS; MOLECULAR SEQUENCE DATA; MUTATION; PHENOTYPE; PROVIRUSES; REVERSE TRANSCRIPTASE INHIBITORS; RNA, VIRAL; SAQUINAVIR; TREATMENT OUTCOME; ZALCITABINE; ZIDOVUDINE;

EID: 0032552167     PISSN: 02699370     EISSN: None     Source Type: Journal    
DOI: 10.1097/00002030-199812000-00008     Document Type: Article

References (32)

1. Craig JC, Duncan IB, Hockley D, Grief C, Roberts NA, Mills JS: Antiviral properties of Ro 31-8959, an inhibitor of HIV proteinase. Antiviral Res 1991, 16:295-305.
2. Craig JC, Whittaker L, Duncan I, Roberts N: In vitro anti-HIV and cytotoxicological evaluation of the triple combination: AZT and ddC with HIV proteinase inhibitor saquinavir (Ro31-8959). Antiviral Chem Chemother 1994, 5:380-386.
3. Kitchen VS, Skinner C, Ariyoshi K, et al.: Safety and activity of saquinavir in HIV infection. Lancet 1995, 345:952-955.
4. Vella S, Galluzzo C, Giannini G, et al.: Saquinavir zidovudine combination in patients with advanced HIV infection and no prior anti-retroviral therapy: CD4+ lymphocyte/plasma RNA changes, and emergence of HIV strains with reduced phenotypic sensitivity. Antiviral Res 1996, 29:91-93.
5. Collier A, Coombs R, Schoenfeld D, et al.: Treatment of HIV infection with saquinavir, zidovudine, and zalcitabine. N Engl J Med 1996, 334:1011-1017.
6. Schapiro JM, Winters M, Stewart F, et al.: The effect of high-dose saquinavir viral load and CD4+ T-cell counts in HIV-infected patients. Ann Intern Med 1996, 124:1039-1050.
7. Kohl NE, Emini EA, Schleif WA, et al.: Active HIV protease is required for viral infectivity. Proc Natl Acad Sci USA 1988, 85:4686-4690.
8. Ho DD, Neumann AU, Perelson AS, Chen W, Leonard JM, Markowitz M: Rapid turnover of plasma virions and CD4 lymphocytes in HIV-1 infection. Nature 1995, 373:123-126.
9. Condra JH, Schleif WA, Blahy OM, et al.: In vivo emergence of HIV-1 variants resistant to multiple protease inhibitors. Nature 1995, 374:569-571.
10. Perelson AS, Essunger P, Cao Y, et al.: Decay characteristics of HIV-1-infected compartments during combination therapy. Nature 1997, 387:188-191.
11. Tisdale M, Myers RE, Maschera B, Parry NR, Oliver NM, Blair ED: Cross-resistance analysis of human immunodeficiency virus type 1 variants individually selected for resistance to five different protease inhibitors. Antimicrob Agents Chemother 1995, 39:1704-1710.
12. Markowitz M, Mo H, Kempf DJ, et al.: Selection and analysis of HIV-1 variants with increased resistance to ABT-538, a novel protease inhibitor. J Virol 1995, 69:701-706.
13. Patick AK, Mo H, Markowitz M, et al.: Antiviral and resistance studies of AG1343, an orally bioavailable inhibitor of HIV protease. Antimicrob Agents Chemother 1996, 40:292-297.
14. Condra J, Holder D, Schlief W, et al.: Genetic correlates of in vivo viral resistance to indinavir, a HIV-1 protease inhibitor. J Virol 1996, 70:8270-8276.
15. Jacobsen H, Yasargil K, Winslow DL, et al.: Characterisation of HIV-1 mutants with decreased sensitivity to proteinase inhibitor Ro 31-8959. Virology 1995, 206:527-534.
16. Jacobsen H, Hänggi M, Ott M, et al.: In vivo resistance to a HIV-1 proteinase inhibitor: mutations, kinetics and frequenies. J Infect Dis 1996, 173:1-9.
17. Erickson JW: The not-so-great escape. Nature Struct Biol 1995, 2:523-528.
18. Rose RE, Gong Y, Greytok JA, et al.: HIV-1 viral background plays a major role in development of resistance to protease inhibitors. Proc Natl Acad Sci USA 1996, 93:1648-1653.
19. Jacobsen H, Hänggi M, Ott M, et al.: Reduced sensitivity to saquinavir: an update on genotyping from Phase 1/11 trials. Antiviral Res 1996, 29:95-97.
20. Eberle J, Bechowsky B, Rose D, et al.: Resistance of HIV type 1 to proteinase inhibitor Ro 31-8959. AIDS Res Hum Retroviruses 1995, 11:671-676.
21. Japour AJ, Mayers DL, Johnson VA, the RV-43 Study group, ACTG Virology Committee Resistance Working Group: Standardized peripheral blood mononuclear cell culture assay for determination of drug susceptibilities of clinical human immunodeficiency virus type 1 isolates. Antimicrob Agents Chemother 1993, 37:1095-1101.
22. Chou TC: The median-effect principle and the combination index for quantitation of synergism and antagonism. In Synergism and Antagonism in Chemotherapy. Edited by Chou TC, Rideout DC. New York: Academic Press; 1991:61-102.
23. Kaye S, Comber E, Tenent-Flowers M, Loveday C: The appearance of drug resistance-associated point mutations in HIV-1 plasma RNA precedes their appearance in proviral DNA. AIDS Res Hum Retroviruses 1995, 11:1221-1224.
24. Stellbrink HJ, the Invirase International Phase III Trial (SV14604) Group: Clinical and survival benefit of saquinavir in combination with zalcitabine and zidovudine in untreated/minimally treated HIV-infected patients. 6th European Conference on Clinical Aspects and Treatment of HIV Infection, Hamburg, October 1997 [abstract 212].
25. Gu Z, Gao Q, Fang H, et al.: Identification of a mutation codon 65 in the IKKK motif of reverse transcriptase that encodes HIV resistance to 2′,3′-dideoxy-3′-thiacytidine. Antimicrob Agents Chemother 1994, 38:275-228.
26. Schinazi RF, Lloyd Jr RM, Nguyen M: Characterisation of human immunodeficiency viruses resistant to oxathiolane-cytosine nucleotides. Antimicrob Agents Chemother 1993, 37:875-881.
27. BHIVA Guidelines Co-ordinating Committee: British HIV association guidelines for antiretroviral treatment of HIV seropositive individuals. Lancet 1997, 349:1086-1092.
28. Smith MS, Koerber KL, Pagano JS: Long-term persistence of zidovudine resistance mutations in plasma isolates of human immunodefficiency virus type 1 of dideoxyinosine-treated patients removed from zidovudine therapy. J Infect Dis 1994, 169:184-1118.
29. Winslow DL, Stack S, King R, Scarnati H, Bincsik A, Otto MJ: Limited sequence diversity of the HIV-1 protease gene from clinical isolates and in vitro susceptibility to HIV protease inhibitors. AIDS Res Human Retroviruses 1995, 11:107-113.
30. Lech WJ, Wang C, Yang YL, et al.: In vivo sequence diversity of the protease of HIV-1: Presence of protease inhibitor resistant variants in untreated subjects. J Virol 1996, 70:2038-2043.
31. Kozal MJ, Shah N, Shen N, et al.: Extensive polymorphisms observed in HIV-1 clade B protease gene using high-density oligonucleotide arrays. Nature Med 1996, 2:753-759.
32. Molla A, Korneyeva M, Gao Q, et al.: Ordered accumulation of mutations in HIV protease confers resistance to ritonavir. Nature Med 1996, 2:760-766.